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Abstract

Elective endovascular aneurysm repair (EVAR) is the first-line therapeutic option for patients with
infrarenal abdominal aortic aneurysm. However, endoleaks –– persistent blood flow outside the lumen
of the stent graft (or endograft) but within the aneurysm sac or adjacent vascular segment being treated
by the graft –– continue to be a persistent problem in the post-EVAR setting. The type II endoleak is
the most common of these and can be a demanding challenge to address by standard endovascular
techniques. Currently, two prominent endovascular techniques exist for the management of type II
endoleaks: direct translumbar embolization and transarterial embolization. Both of these are fraught
with their own limitations and complications. In this review, we describe the contemporary trends in
management of type II endoleaks and introduce a novel endovascular technique to treat this challenging
and common EVAR complication.
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Elective endovascular aneurysm repair (EVAR)
has emerged as the first-line therapeutic option for
patients with infrarenal abdominal aortic aneurysms
(AAA)1-3 that have a diameter of at least 5.0–5.5 cm. This
is because all-cause perioperative mortality, as well as
AAA-related mortality at short- and intermediate-term
follow-up, is lower in EVAR than open surgical repair.4
Although beset with a spectrum of complications that
have no surgical counterparts (Box 1), the most common
and often challenging complication is the endoleak,
defined by persistent blood flow outside the lumen of
the stent graft (or endograft) but within the aneurysm
sac or adjacent vascular segment being treated by the
graft. An endoleak usually is evidence of incomplete
exclusion of the aneurysm from the circulation with
resulting elevated systemic pressures in the aneurysm
sac. Endoleaks are traditionally classified into types
I through IV, with types I and III often requiring
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immediate reintervention because they are associated
with a high risk of aneurysm rupture.2 A complex array
of factors –– device construction, collateral pattern,
amount of aneurysmal clot, spontaneous thrombosis
and secondary interventions –– influence the incidence
of endoleaks.
Box 1. Complications post-endovascular
aneurysm repair
1. Endoleak
2. Endograft infection
3. Endograft thrombosis
4. Endograft migration
5. Peripheral microembolism
6. Access site bleeding/hematoma
7. Late rupture

Figure 1 outlines the types of endoleaks based on
information regarding the course of blood flow into
the aneurysm sac. As shown, a type II endoleak
(T2E) –– the most common endoleak encountered
post-EVAR –– is due to persistent retrograde blood
flow from aortic side branches, such as the inferior
Review

Figure 1. Schematic for the classification of en-

doleaks. A type I endoleak indicates persistent “perigraft”
channel(s) of blood flow caused by an inadequate sealing at the proximal (type Ia) or distal (type Ib) end of the
endograft. In the case of an aortomonoiliac prosthesis,
a type I endoleak also may refer to blood flow around
an iliac occluded plug (type Ic). A type II endoleak is due
to retrograde blood flow, or “retroleak,” from a single
vessel (usually the inferior mesenteric artery –– type IIa),
lumbar arteries (type IIb –– two vessels or more) or other
collateral blood vessels. Endoleaks caused by disconnection of a component of the endograft are classified
as type IIIa (junctional separation of the modular components) or type IIIb if caused by fabric tear, fabric disruption or disintegration of the graft material. Based on size,
these endoleaks are further subdivided as major (>2
mm) or minor (<2 mm). A type IV endoleak is caused by
blood flow through an intact but otherwise porous fabric
material of the endograft and, by definition, is classified
as type IV only if detected within the first month after
endovascular aneurysm repair. An endoleak visualized
by imaging studies but without precise identification of
the source is classified as one of undefined origin. Some
authors also use the term type V endoleak for endotension, a poorly understood phenomenon in which there
is continued expansion of the aneurysm sac without
evidence of a true leak site.

mesenteric artery (type IIa, 33%), lumbar arteries (type
IIb, 64%) or other collateral blood vessels (accessory
renal arteries, internal iliac arteries, gonadal, median
sacral artery, 3%), into the perigraft space (aneurysm
sac). Incidence of post-EVAR T2E has been identified
in the range of 10.2–45%,5-8 varying according to
the sensitivity of the diagnostic method used. These
leaks typically are found during routine ultrasound or
computed tomography (CT) follow-up for EVAR.
Although most T2Es resolve spontaneously within
a few months or remain benign,9-12 persistent T2Es
can be associated with sac expansion and, therefore,
require secondary intervention10 to avoid rupture.
Currently, two major endovascular techniques exist
for the management of T2Es: direct translumbar
embolization (TLE) and transarterial embolization
(TAE). TLE is believed to be more effective for treating
a T2E13 because the technique allows for direct needle
access into the aneurysm sac as close as possible to the
“nidus of the leak,” which can then be eliminated more
Review

effectively, analogous to central nidus embolization of
an arteriovenous malformation. The challenge of this
technique lies in precise advancement and positioning
of the needle, using either fluoroscopy or CT as the
guiding modality. There are many instances in which
TLE is not feasible because of the location of the
endoleak relative to the inferior vena cava, bowel
loops or kidney, or its location in the pelvis, where safe
needle access is not possible due to surrounding bony
structures.
In this report, we first describe a novel transgraft
embolization (TGE) technique that utilizes laser energy
to micropuncture the endograft via a transfemoral
arterial approach, allowing access to the aneurysm sac
at the precise site of the endoleak nidus irrespective
of its location. A review of the recent literature on
EVAR of infrarenal AAA follows to put this innovative
technique into context with contemporary standards of
care.
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Figure 2. Composite aorto-

grams and computed tomography angiographic (CTA) views of
the abdominal aorta of a 79-yearold man with several vascular
disease risk factors. A: Aortogram obtained prior to endovascular aneurysm repair (EVAR)
of a 6-cm infrarenal abdominal
aortic aneurysm (AAA). B: Aortogram obtained immediately postEVAR procedure demonstrating
no endoleak and a well-positioned endoprosthesis. C:
Follow-up CTA obtained 1 month
after EVAR (endoprosthesis indicated by yellow arrow) revealing
a small type II endoleak (red arrow). Also shown is an aneurysm
sac with a diameter of 6.2 cm
(blue bar/arrow). D: Follow-up
CTA at 18 months demonstrating
aneurysm sac growth to 7.4 cm
(blue bar/arrow) with a persistent
type II endoleak (red arrow). At
this stage, a decision was made
to intervene on the endoleak.

CASE DESCRIPTION

A 79-year-old man with a history of hypertension,
dyslipidemia, diabetes mellitus and stable coronary
heart disease had undergone successful EVAR
for infrarenal AAA with a Gore® Excluder® AAA
Endoprosthesis (W. L. Gore & Associates Inc.,
Flagstaff, AZ) (Figure 2A/2B). Routine post-EVAR
CT scan at 1-month screening revealed a mild T2E
(Figure 2C, red arrow) with an aneurysm sac diameter
of 6.2 cm (Figure 2C, blue bar). However, a follow-up
CT scan 18 months post-EVAR showed aneurysm sac
growth to 7.4 cm with a persistent T2E (Figure 2D).
Although addressing this patient’s T2E using TLE
was considered, detailed CT evaluation showed this
approach would be complicated by the neighboring
pelvic bony structures as well as the inferior vena cava.
Thus, we decided to approach the T2E with our novel
TGE technique.
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Procedure
After detailed analysis (CT reconstruction) of the
CT angiogram (Figure 2D and Figure 3A), taking
into account the location of the T2E with respect to
the limbs of the endoprosthesis, we determined that
the right limb of the endoprosthesis provided the
most immediate access to the endoleak. Following
percutaneous catheterization of the right common
femoral artery using ultrasound to determine patency
and guide needle entry, a 6-French 20-cm sheath was
advanced over a standard 0.038-inch guidewire. This
was followed by the introduction of an angiographic
catheter (Soft-Vu® Omni Flush, AngioDynamics,
Latham, NY) at the level of the superior mesenteric
artery to obtain an aortogram (Figure 3B) in order
to rule out a type Ia leak and, importantly, study late
arterial filling of the type II leak, which can be supplied
by superior mesenteric artery collaterals. Through the
sheath, a 6-French internal mammary artery coronary
Review

Figure 3. This angiographic collage depicts the transgraft embolization (TGE) technique used for management of a

type II endoleak (T2E) in a 79-year-old patient with aneurysm sac growth up to 7.4 cm post-endovascular aneurysm
repair. A: Outlay of the aneurysm sac (blue arrow), endoprosthesis (yellow arrow) and T2E (small red arrows). Computed tomography (CT) angiogram precisely localizes the position of the endoleak nidus. Based on this, the operator
is able to determine the vascular approach (right or left limb of the endograft) to precisely puncture the endograft. B:
Right anterior oblique aortogram (with red arrows depicting angulation of the fluoroscopic C-arm based on previous
CT localization) obtained with an omniflush catheter (black arrow). Often, additional angiography is performed with the
catheter close to the hypogastric artery, which will generally connect to the leak via lumbar collaterals. C–E: Progressive advancement of the Turbo-Elite™ catheter (Spectranetics Corp., Colorado Springs, CO) to puncture the graft material precisely at the site of the endoleak (blue arrow = internal mammary artery catheter, red arrows = Turbo-Elite). A
radiopaque marker is located on the distal end of the laser catheter to aid localization. F: Advancement of the 0.014inch guidewire (green arrows) into the aneurysm sac. G: Introduction of the 2.4-French microcatheter (Echelon™, ev3
Endovascular Inc., Plymouth, MN) over the guidewire into the aneurysm sac (arrow). H–L: Successive steps in the
administration of Onyx 18 (ev3 Neurovascular) (orange arrows) through the microcatheter to obliterate the T2E at the
level of the nidus. In Panel L, the stent-graft limb is seen after the removal of the microcatheter. Note the absence of
contrast extravasation at the puncture site.
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Box 2. Risk factors for persistent type II
endoleak

Figure 4. Computed tomographic angiography (CTA)
obtained 1 year after embolization shows sustained
success. Note sac regression (approximately 6.4 cm)
compared to preembolization CTA (7.4 cm, Figure 2D).

guide catheter was advanced to the level of the proximal
limb of the endograft (Figure 3C, blue arrow). In the
right anterior oblique 30-degree projection, the graft
material was punctured successfully using a 0.9-mm
coronary laser probe (Turbo-Elite™, Spectranetics
Corp., Colorado Springs, CO) (Figure 3D/3E, red
arrow) precisely at the site of the endoleak. A 0.014-inch
guidewire was advanced into the aneurysm sac (Figure
3F, green arrows), and the probe was removed and
exchanged for a 2.4-French microcatheter (Echelon™,
ev3 Endovascular Inc., Plymouth, MN) (Figure 3G).
Through the catheter, selective digital subtraction
angiography showed the endoleak at the same level
(Figure 3H, orange arrows) and also demonstrated
some unnamed vascular structures (Figure 3H, yellow
arrow). Four vials of Onyx® 18 (ev3 Neurovascular,
Irvine, CA) were administered through the catheter
to obliterate the T2E at the level of the nidus (Figure
3I–3L). The final angiogram (Figure 3L) revealed
excellent results with complete obliteration of the T2E.
One year later, the follow-up computed tomography
angiogram (CTA) showed decreased aneurysm sac
size (Figure 4) compared to preembolization.

DISCUSSION

Natural History, Risk Factors
and Surveillance of T2E Post-EVAR
The major risk with T2Es is continued aneurysm
122 JPCRR • Volume 2, Issue 3 • Summer 2015

1. Patent inferior mesenteric artery
2. Increased number of patent individual L2,
		 L3 and L4 lumbar arteries
3. Increased total number of patent lumbar
		arteries
4. Aneurysm sac without thrombus
5. Endoleaks that persist on computed
		 tomography imaging in both arterial and
		 delayed phases
6. Endoleak cavity > 15 mm in maximum
		 diameter, 1.35 cm3 in volume
7. Endoleak cavity with feeding vessels
		 3.2 mm in diameter or larger
8. *High velocity endoleaks (>80 cm/s)
9. *Unidirectional flow in endoleak
10. *Contrast washout time from aneurysm
sac ≥ 520 seconds
*Ultrasound findings.

sac expansion and possible rupture.14 Aneurysm
sac expansion is defined as growth of 5 mm beyond
the preoperative maximal sac diameter. T2Es are
not related to any specific design or material of the
endograft used,15 although some risk factors for their
development are identified in Box 2. A T2E may appear
immediately at the time of graft implantation (primary
endoleak), at the first follow-up imaging study, or
months or years after EVAR. Although evaluation of
the natural history of persistent endoleaks is difficult
because of the varying management strategies used
to address these leaks, a systematic review of 32
nonrandomized, retrospective studies found that
35.4% of T2Es resolved spontaneously, whereas 0.9%
of aneurysms with isolated T2Es ruptured.6 It also is
important to note that whereas a persistent T2E is a
significant factor for continued sac expansion, a small
number of aneurysms with T2Es have been reported
to rupture without sac expansion.6 Recently it was
reported that there is a high incidence of secondary
intervention (20%), continued aneurysm sac growth
(37.9%) and a need for graft explantation (8.4%) in
patients with T2Es.16,17
Because of the development of endoleaks, EVAR
patients require long-term surveillance with serial
Review

radiologic imaging. Surveillance CT scans or
ultrasounds are directed toward determining: a) the
integrity of the graft, b) the presence of flow within
the aneurysm sac (endoleak), and c) the size of the
aneurysm sac. Institutions have differing protocols for
post-EVAR monitoring based on their staff’s expertise
with different imaging modalities.17,18 The Society for
Vascular Surgery recommends triple-phase CTA at
30 days and 12 months in its published guidelines on
post-EVAR surveillance.2 If the 30-day CTA reveals an
endoleak or aneurysm sac growth, a 6-month CTA is
recommended. If the 30-day and 12-month CTA scans
reveal no endoleak, device abnormality or aneurysm
sac enlargement, annual color duplex ultrasound
can be used as an alternative to CTA if performed
by a skilled technician in an accredited noninvasive
vascular laboratory.
CTA may not be able to identify all endoleaks (e.g.
occult endoleaks) in patients with aneurysm sac growth
nor all feeding vessels in patients with apparent T2Es.19
Therefore, it has been suggested that a new generation
of magnetic resonance imaging (MRI) contrast agents
(e.g. gadofosveset trisodium) may better detect lowflow leaks.17 However, because of its own limitations
(i.e. not all endografts are compatible with MRI, not
all patients can undergo MRI etc.), further studies will
be needed before MRI can present a real challenge to
CTA.
Pressure sensors can be implanted inside the aneurysm
sac at the time of EVAR to serve as another modality
to identify and monitor endoleaks. Currently, the
EndoSure™ (CardioMEMS Inc., Atlanta, GA), a
resonant circuit powered by an external radiofrequency
antenna, is the only pressure sensor approved by
the U.S. Food and Drug Administration.17 Several
studies have shown its efficacy in detecting type I
and II endoleaks.20,21 Because the safety, long-term
complications, efficacy and accuracy of pressure
sensor use related to T2Es is under debate, this method
remains an adjunct to standard imaging modalities
until more clinical data is available.17,22,23
Management of Type II Endoleak
Although European guidelines for T2Es recommend
reintervention in patients with increased sac diameter
≥ 10 mm (evidence level: 2b),3 explicit guidelines are
Review

lacking in the United States. However, most clinicians
will offer reintervention for patients with T2Es who
have aneurysm sac growth of > 5 mm or persistent
endoleaks (>6 months). Current imaging practices
most often result in an underestimation of the size and
complexity of endoleaks. The EUROSTAR study found
that combined adverse outcome events (aneurysm
growth, transfemoral interventions and transabdominal
secondary procedures) occurred in 55% of patients
with T2Es compared to 15% in patients without any
leak.24 Other studies reported finding signs of previous
endoleaks in post-EVAR aneurysm ruptures; therefore,
endoleaks are aggressively evaluated and treated if
they persist beyond the 6-month follow-up, unless the
aneurysm sac has shrunk.14,25,26
Because persistent T2Es are significant contributors
to late adverse outcomes such as aneurysm rupture,
conversion to open repair, aneurysm sac growth and
the need for reintervention, several treatment options
are available for the management of T2Es (Box 3).
However, the management of T2Es is hotly debated
because of diverse personal experience and beliefs
concerning the long-term outcome of the various
approaches. T2Es are complex vascular structures
that contain an endoleak cavity, or nidus, with several
feeding and draining vessels similar to an arterial venous
malformation. Effective treatment requires complete
obliteration of the nidus, with resulting permanent
cessation of flow in all the vessels involved. Partial
or incomplete elimination will lead to recurrence and
continued risk of aneurysm growth and rupture. Thus,
obliteration of T2Es can be challenging and requires
advanced endovascular skills.
Transfemoral and translumbar embolization are
the commonly used techniques in contemporary
practice.16,27-31 Higher failure rates with femoral TAE
compared to TLE (80% vs. 8%) are believed to be
due to embolization of a single vessel and failure to
completely obliterate the central nidus and the feeding
vessel(s) in the first attempt. Of interest, comparable
success rates (72% vs. 78%) have been reported16,32
when both the feeding artery and endoleak cavity are
embolized.17
TAE involves retrograde catheterization using
microcatheters with occlusion by coiling or embolic
www.aurora.org/jpcrr
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Box 3. Management strategies for type II
endoleak
Reintervention
1. Transarterial embolization
2. Translumbar embolization
3. Transgraft embolization
4. Transcaval embolization
5. Transfemoral transsealing embolization
6. Open and laparoscopic ligation of the lumbar
and mesenteric arteries
7. Laparotomy with plication of the endoleak
source within the aneurysm sac
8. Total robotic ligation of the inferior
mesenteric artery
9. Endograft explantation for continued growth
after endovascular reintervention failure
(8–10% of cases)
Preemptive/preventive intervention* (for
occluding potential sources of collateral
inflow)
1. Placement of Onyx, thrombogenic absorbable
sponge, polyurethane foam or fibrin glue
concurrent to the deployment of the endograft
2. Selective preoperative embolization of large
inferior mesenteric arteries†
*Those who oppose the preemptive approach to
type II endoleak (T2E) suggest such treatment
is not warranted due to the low incidence of
T2Es with aneurysm sac growth coupled with
the risks and costs of preemptive treatment. The
clot engineering concept for T2E prevention will
lead to future research in the field of biomaterials
and polymers. Preemptively occluding potential
sources of collateral inflow has been widely
accepted for some branch vessels such as the
internal iliac artery (IIA). If the distal landing zone
does not allow for a seal above the IIA (a common
problem due to ectatic common iliac arteries
associated with abdominal aortic aneurysm),
occlusion of one IIA is commonly performed before
endovascular aneurysm repair with use of coils
or other occlusion devices like the Amplatzer®
vascular plug (AGA Medical, Golden Valley, MN).
Bilateral IIA occlusion, however, is avoided due
to a high incidence of postoperative intractable
buttock claudication.
The value of this approach has never been
verified or adopted on a large scale.

†
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materials. Inflow and outflow vessels are embolized.
In T2Es involving the internal mesenteric artery, the
middle colic artery is selected through the superior
mesenteric artery and retrograde access to the internal
mesenteric artery is gained through the marginal artery.
T2Es involving the lumbar arteries are accessed through
retrograde cannulation of the iliolumbar arteries from
the internal iliac arteries.17
During TLE, the aneurysm sac is directly punctured
with a spinal needle under fluoroscopic or CT guidance
while the patient is in the prone position, typically
from a left paraspinal approach. Optimal needle entry,
anatomical landmarks and depth can be predicted by
CT imaging. The goal is to access the nidus of the
endoleak, which can be confirmed by pulsatile flow.
The endoleak nidus is then embolized with liquid
agents or coils, similar to TAE.17
Repeat interventions are required in an estimated
2–20% of cases regardless of whether TAE or TLE was
used,8,16,32,33 usually because the culprit vessels were
not adequately identified or treated during the initial
embolization. This statistic underscores the importance
of complete obliteration of the nidus of the endoleak.17
The innovative transgraft embolization technique
we’ve adopted allows a transarterial route, usually
transfemoral, with predictable puncture of the
endograft close to the nidus of the T2E. Utilizing a
multifiber coronary laser rapid exchange atherectomy
catheter consisting of optical fibers encased within a
polyester shaft, ultraviolet energy is transmitted from
the excimer laser system (CVX-300®, Spectranetics)
to the endoprosthesis to photoablate the graft material.
(Photoablation is the process by which energy
photons cause molecular bond disruption without
thermal damage to surrounding tissue.) Once access is
gained to the aneurysm sac, a coronary microcatheter
(Echelon 10, ev3 Endovascular) is advanced over a
0.014-inch coronary wire into the sac as close to the
nidus as possible. The Echelon family of over-thewire microcatheters (nitinol braided design) is based
on a unique technological platform that provides
exceptional pushability and trackability and allows
more flow in the guide catheter, which can be useful
for angiographic injections. Insertion of the coronary
microcatheter is then followed by the injection of
Review

liquid embolic agent Onyx 34 (ev3 Neurovascular),
an ethylene-vinyl-alcohol copolymer dissolved in
dimethyl sulfoxide (DMSO). Micronized tantalum
powder is suspended in the liquid polymer/DMSO
mixture to provide radiopacity. Onyx is therefore a
premixed, radiopaque, injectable embolic agent that is
not a glue, has no adhesive properties and solidifies
through the process of precipitation. Precipitation
is initiated when Onyx comes into contact with an
aqueous solution (e.g. blood, body fluids, normal saline,
water) and the solvent DMSO rapidly diffuses out of
the polymer mass, thus causing in situ precipitation
of a soft radiopaque polymeric embolus. Onyx is first
slowly injected to displace the DMSO, and then the
injection is continued at a slow, steady rate under
optimal fluoroscopic control to avoid occlusion of
nontarget vessels. The distance that Onyx travels before
solidifying within the vasculature depends on a number
of factors, including the flow rate in the vessel and the
rate of injection. After completion of the injection,
the microcatheter is removed by gently pulling during
slight aspiration. Currently, Onyx is rapidly gaining
increasing acceptance as a promising liquid embolic
agent of choice for complete occlusion of the nidus of a
T2E, a mandatory step in the reintervention technique.
Implementing TGE to treat the persistent T2E described
here demonstrates the value of using a modified
transarterial approach in locating and successfully
eliminating the nidus of the endoleak while avoiding
the more cumbrous TLE procedure. For this case,
1-year follow-up CTA showed regression of the
aneurysm sac, indicative of complete T2E obliteration
(Figure 4).

CONCLUSION

Even though endovascular aneurysm repair has
emerged as the first-line management strategy in
patients with infrarenal abdominal aortic aneurysm,
reintervention after EVAR continues to be an
important issue, primarily due to persistent type II
endoleaks. The results of contemporary secondary
interventions for management of T2Es (transarterial
or translumbar embolization) are suboptimal due to
incomplete embolization/elimination of the endoleak
cavity or nidus. Transgraft embolization is an attractive
treatment alternative to TLE or TAE because it allows
for precise and predictable endovascular access to the
Review

nidus of the endoleak and a better embolization result.
In our practice, TGE has completely replaced TAE and
TLE. We are in the process of analyzing the results of
this novel technique.
Patient-Friendly Recap
• Aneurysms that form around the aorta are usually
repaired using stent grafts.
• Subsequent arterial leaks are a common
complication of this endovascular repair.
• Successfully treating a persistent leak using
traditional methods can be difficult due to nearby
body structures.
• The authors report a novel endovascular technique
called transgraft embolization, which delivers
specialized liquid agents through microcatheters to
effectively eliminate this type of endoleak.
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